Prof. Doron Levy's Presentation
to the United States House of Representatives (Sep. 23, 2008)

Leukemia is a cancer of the blood that is characterized by an abnormal production of white blood cells. The treatment of Chronic Myelogenous Leukemia (CML) was revolutionized over the past decade with the introduction of new molecular-targeted drugs such as Imatinib. While these drugs keep leukemia in most patients in remission, they do not cure the disease.

Mathematical modeling combined with new experimental data, suggests the feasibility of a low-risk, clinical approach to enhancing the effect of the drug therapy, possibly leading to a durable cure of the disease.